Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity

European Journal of Clinical Pharmacology

Volumn 63, Issue 10, 2007, Pages 901-908

  Wasmuth, J C ^a   Lambertz, I ^a   Voigt, E ^a   Vogel, M ^a   Hoffmann, C ^b   Burger, D ^c   Rockstroh, J K ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HAART; HIV; Indinavir; Reduced dose; Ritonavir

Indexed keywords

BILIRUBIN; CHOLESTEROL; CREATININE; INDINAVIR; RITONAVIR; TRIACYLGLYCEROL;

ADULT; AGED; ANALYTICAL PARAMETERS; ANTIVIRAL ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INCIDENCE; MALE; METABOLIC DISORDER; NEPHROTOXICITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SKIN TOXICITY; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; VIRUS LOAD;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; GERMANY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERTENSION; INDINAVIR; KIDNEY DISEASES; MALE; METABOLIC DISEASES; MIDDLE AGED; PROSPECTIVE STUDIES; RITONAVIR; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34548591632     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0343-z     Document Type: Article

References (22)

1. Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fatkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H (2000) Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group. Aids 14(9):1181-1185
2. Voigt E, Wickesberg A, Wasmuth JC, Gute P, Locher L, Salzberger B, Wohrmann A, Adam A, Weitner L, Rockstroh JK (2002) First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Med 3(4):277-282
3. Dieleman JP, Salahuddin S, Hsu YS, Burger DM, Gyssens IC, Sturkenboom MC, Stricker BH, Kok DJ (2001) Indinavir crystallization around the loop of Henle: experimental evidence. J Acquir Immune Defic Syndr 28(1):9-13
4. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM (1999) Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. Aids 13(4):473-478
5. Aarnoutse RE, Wasmuth JC, Fatkenheuer G, Schneider K, Schmitz K, de Boo TM, Reiss P, Hekster YA, Burger DM, Rockstroh JK (2003) Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma concentrations of indinavir. Antivir Ther 8(4):309-314
6. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV (2000) Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 30(Suppl 2):S151-S159
7. Burger DM, Aarnoutse RE, Hugen PW (2002) Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis 15(1):17-22
8. Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit A, Ruxrungtham K, Ubolyam S, Stek M, Cooper D, Lange J, Phanupak P, Reiss P (2003) Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 51(5):1231-1238
9. Rayner CR, Esch LD, Wynn HE, Eales R (2001) Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen. Ann Pharmacother 35(11):1391-1395
10. Konopnicki D, De Wit S, Poll B, Crommentuyn K, Huitema A, Clumeck N (2005) Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily. HIV Med 6(1):1-6
11. Duvivier C, Myrto A, Marcelin AG, Ghosn J, Ait-Mohand H, Schneider L, Agher R, Bricaire F, Costagliola D, Calvez V, Peytavin G, Katlama C (2003) Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antivir Ther 8(6):603-609
12. Ghosn J, Lamotte C, Ait-Mohand H, Wirden M, Agher R, Schneider L, Bricaire F, Duvivier C, Calvez V, Peytavin G, Katlama C (2003) Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. Aids 17(2):209-214
13. Wasmuth JC, la Porte CJ, Schneider K, Burger DM, Rockstroh JK (2004) Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). Antivir Ther 9(2):213-220
14. Hugen PW, Verweij-van Wissen CP, Burger DM, Wuis EW, Koopmans PP, Hekster YA (1999) Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 727(1-2):139-149
15. Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, Sangkote J, Bunyaprawit P, Horsakulchai M, Lange J, Cooper D, Phanuphak P, Ruxrungtham K (2005) Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther 10(2):301-307
16. Aarnoutse RE, Grintjes KJ, Telgt DS, Stek M Jr, Hugen PW, Reiss P, Koopmans PP, Hekster YA, Burger DM (2002) The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 71(1):57-67
17. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD (2003) Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis 188(5):635-642
18. Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P (2005) Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes. Antivir Ther 10(8):911-916
19. Boubaker K, Sudre P, Bally F, Vogel G, Meuwly JY, Glauser MP, Telenti A (1998) Changes in renal function associated with indinavir. Aids 12(18):F249-254
20. Sarcletti M, Petter A, Romani N, Lhotta K, Konig P, Maier H, Zangerle R (2000) Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol 54(4):261-270
21. Boyd MA, Siangphoe U, Ruxrungtham K, Reiss P, Mahanontharit A, Lange JM, Phanuphak P, Cooper DA, Burger DM (2006) The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J Antimicrob Chemother 57(6):1161-1167
22. Hsu A, Granneman GR, Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti- HIV agents. Clin Pharmacokinet 35(4):275-291